Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Flagship Ventures Fund IV General Partner LLC. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Flagship Ventures Fund IV General Partner LLC har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:EVLO / Evelo Biosciences, Inc. | 10% Owner | 3.931.685 |
US:AXLA / Axcella Health Inc. | 10% Owner | 3.048.780 |
US:RUBY / Rubius Therapeutics, Inc. | 10% Owner | 2.633.703 |
US:KLDO / Kaleido Biosciences, Inc. | 10% Owner | 738.333 |
US:MCRB / Seres Therapeutics, Inc. | 10% Owner | 0 |
US:MRNA / Moderna, Inc. | Director, 10% Owner | 0 |
US:TMDX / TransMedics Group, Inc. | 10% Owner | 0 |
US:SYRS / Syros Pharmaceuticals, Inc. | 10% Owner | 0 |
US:EBIO / Eleven Biotherapeutics, Inc. | 10% Owner | 106.787 |
US:EDIT / Editas Medicine, Inc. | 10% Owner | 0 |
US:TTOO / T2 Biosystems, Inc. | 10% Owner | 0 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Flagship Ventures Fund IV General Partner LLC. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb CARM / Carisma Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CARM / Carisma Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb EDIT / Editas Medicine, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg EDIT / Editas Medicine, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb EVLO / Evelo Biosciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg EVLO / Evelo Biosciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb KLDO / Kaleido Biosciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg KLDO / Kaleido Biosciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb MCRB / Seres Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg MCRB / Seres Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SYRS / Syros Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SYRS / Syros Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TMDX / TransMedics Group, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i CARM / Carisma Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TMDX / TransMedics Group, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i CARM / Carisma Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Flagship Ventures Fund IV General Partner LLC som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 3.246.753 | 3.931.685 | 474,03 | 2,31 | 7.499.999 | 9.082.192 | |
2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.082.251 | 1.493.241 | 263,33 | 2,31 | 2.500.000 | 3.449.387 | |
2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.082.251 | 1.493.241 | 263,33 | 2,31 | 2.500.000 | 3.449.387 | |
2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 3.048.780 | 3.048.780 | 1,64 | 4.999.999 | 4.999.999 | ||
2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 919.111 | 6.299.611 | 17,08 | 1,64 | 1.507.342 | 10.331.362 | |
2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 914.634 | 5.380.500 | 20,48 | 1,64 | 1.500.000 | 8.824.020 | |
2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 2.757.333 | 14.101.638 | 24,31 | 1,64 | 4.522.026 | 23.126.686 | |
2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 2.743.902 | 11.344.305 | 31,90 | 1,64 | 4.499.999 | 18.604.660 | |
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 13.698.630 | 13.698.630 | 1,46 | 20.000.000 | 20.000.000 | ||
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 6.849.315 | 8.219.791 | 499,78 | 1,46 | 10.000.000 | 12.000.895 | |
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.369.863 | 5.495.324 | 33,21 | 1,46 | 2.000.000 | 8.023.173 | |
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.095.890 | 1.887.419 | 138,45 | 1,46 | 1.599.999 | 2.755.632 | |
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 4.383.561 | 7.590.873 | 136,67 | 1,46 | 6.399.999 | 11.082.675 | |
2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.579.843 | 4.465.866 | 54,74 | 1,91 | 3.017.500 | 8.529.804 | |
2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 947.905 | 2.004.657 | 89,70 | 1,91 | 1.810.499 | 3.828.895 | |
2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 3.791.623 | 8.600.403 | 78,85 | 1,91 | 7.242.000 | 16.426.770 | |
2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70.000 | 2.633.703 | 2,73 | 29,00 | 2.030.000 | 76.377.387 | |
2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70.000 | 2.633.703 | 2,73 | 29,00 | 2.030.000 | 76.377.387 | |
2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70.000 | 15.393.593 | 0,46 | 29,00 | 2.030.000 | 446.414.197 | |
2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71.667 | 738.333 | 10,75 | 11,50 | 824.170 | 8.490.830 | |
2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71.667 | 738.333 | 10,75 | 11,50 | 824.170 | 8.490.830 | |
2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71.666 | 1.685.444 | 4,44 | 11,50 | 824.159 | 19.382.606 | |
2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 46.429 | 4.125.461 | 1,14 | 15,00 | 696.435 | 61.881.915 | |
2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 37.143 | 1.370.476 | 2,79 | 15,00 | 557.145 | 20.557.140 | |
2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 37.143 | 1.370.476 | 2,79 | 15,00 | 557.145 | 20.557.140 | |
2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 9.285 | 791.529 | 1,19 | 15,00 | 139.275 | 11.872.935 | |
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -43.154 | 0 | -100,00 | ||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -1.481.481 | 2.962.963 | -33,33 | ||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -1.186.310 | 3.258.134 | -26,69 | ||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -966.234 | 0 | -100,00 | ||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -642.180 | 1.283.282 | -33,35 | ||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -3.587.820 | 4.434.600 | -44,72 | ||||
2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -2.053.049 | 0 | -100,00 | ||||
2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1.449.190 | 4.971.576 | -22,57 | ||||
2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -7.550.810 | 14.435.589 | -34,34 | ||||
2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.666.667 | 4.079.032 | 69,09 | 3,75 | 6.250.001 | 15.296.370 | |
2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.333.333 | 1.333.333 | 3,75 | 4.999.999 | 4.999.999 | ||
2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.333.333 | 1.333.333 | 3,75 | 4.999.999 | 4.999.999 | ||
2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 333.333 | 782.244 | 74,25 | 3,75 | 1.249.999 | 2.933.415 | |
2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666.666 | 666.666 | 7,50 | 4.999.995 | 4.999.995 | ||
2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666.667 | 2.910.972 | 29,70 | 7,50 | 5.000.002 | 21.832.290 | |
2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666.667 | 2.910.972 | 29,70 | 7,50 | 5.000.002 | 21.832.290 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -10.746 | 6.420.766 | -0,17 | 70,18 | -754.113 | 450.584.959 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -69.254 | 6.431.512 | -1,07 | 69,45 | -4.809.448 | 446.645.998 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -56.406 | 21.986.399 | -0,26 | 70,18 | -3.958.353 | 1.542.919.735 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -363.594 | 22.042.805 | -1,62 | 69,45 | -25.250.331 | 1.530.795.657 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -367 | 6.500.766 | -0,01 | 72,44 | -26.584 | 470.886.236 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -2.551 | 6.501.133 | -0,04 | 71,51 | -182.433 | 464.924.626 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -3.900 | 6.503.684 | -0,06 | 70,46 | -274.780 | 458.226.161 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -7.443 | 6.507.584 | -0,11 | 68,81 | -512.185 | 447.814.838 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -23.199 | 6.515.027 | -0,35 | 67,15 | -1.557.822 | 437.486.669 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -42.540 | 6.538.226 | -0,65 | 65,77 | -2.797.690 | 429.993.625 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -1.933 | 22.406.399 | -0,01 | 72,44 | -140.017 | 1.623.009.752 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -13.408 | 22.408.332 | -0,06 | 71,51 | -958.861 | 1.602.511.695 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -20.492 | 22.421.740 | -0,09 | 70,46 | -1.443.793 | 1.579.755.082 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -39.082 | 22.442.232 | -0,17 | 68,81 | -2.689.404 | 1.544.348.730 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -121.771 | 22.481.314 | -0,54 | 67,15 | -8.176.971 | 1.509.629.228 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -223.314 | 22.603.085 | -0,98 | 65,77 | -14.686.491 | 1.486.516.748 | |
2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.900.000 | 2.886.023 | 192,69 | 4,75 | 9.025.000 | 13.708.609 | |
2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 380.000 | 1.056.752 | 56,15 | 4,75 | 1.805.000 | 5.019.572 | |
2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.520.000 | 4.808.780 | 46,22 | 4,75 | 7.220.000 | 22.841.705 | |
2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -2.281.179 | 0 | -100,00 | ||||
2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1.610.000 | 6.580.766 | -19,66 | ||||
2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -8.390.000 | 22.826.399 | -26,88 | ||||
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -38.366 | 8.190.766 | -0,47 | 18,65 | -715.710 | 152.797.102 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -199.935 | 31.216.399 | -0,64 | 18,65 | -3.729.747 | 582.335.680 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -4.092 | 8.229.132 | -0,05 | 18,96 | -77.579 | 156.012.822 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -21.325 | 31.416.334 | -0,07 | 18,96 | -404.292 | 595.609.710 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -27.714 | 8.233.224 | -0,34 | 18,99 | -526.408 | 156.384.327 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -144.423 | 31.437.659 | -0,46 | 18,99 | -2.743.199 | 597.133.183 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1.735.720 | 0 | -100,00 | ||||
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1.207.658 | 8.260.938 | -12,75 | ||||
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -6.292.342 | 31.582.082 | -16,61 | ||||
2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -248.379 | 0 | -100,00 | ||||
2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -61.537 | 0 | -100,00 | ||||
2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -1.061.102 | 0 | -100,00 | ||||
2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -1.469.173 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -895.255 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -89.525 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -358.102 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -151.643 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -617.914 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -222.506 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -1.005.413 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -928.074 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -386.697 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series A Preferred Stock |
C - Conversion | -4.153.847 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series A Preferred Stock |
C - Conversion | -1.384.615 | 0 | -100,00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 500.000 | 986.023 | 102,88 | 20,00 | 10.000.000 | 19.720.460 | |
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 486.023 | 486.023 | |||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 48.602 | 676.752 | 7,74 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 194.409 | 3.288.780 | 6,28 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 82.324 | 628.150 | 15,08 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 335.457 | 3.094.371 | 12,16 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 120.795 | 1.761.029 | 7,36 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 545.826 | 545.826 | |||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 503.840 | 2.758.914 | 22,34 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 209.933 | 1.640.234 | 14,68 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 2.255.074 | 2.255.074 | |||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 751.691 | 1.430.301 | 110,77 | ||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3.393.050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4.750.270 | ||||||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -1.682.665 | 0 | -100,00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series F Convertible Preferred Stock |
C - Conversion | -450.958 | 0 | -100,00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -600.000 | 0 | -100,00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1.257.465 | 0 | -100,00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series F Convertible Preferred Stock |
C - Conversion | -992.110 | 0 | -100,00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -1.400.000 | 0 | -100,00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -2.000.000 | 0 | -100,00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
C - Conversion | 792.366 | 1.061.102 | 294,85 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
C - Conversion | 1.254.888 | 1.469.173 | 585,62 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | 268.736 | 268.736 | |||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -940.579 | 0 | -100,00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | 214.285 | 214.285 | |||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -750.000 | 0 | -100,00 | ||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697.306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751.757 | ||||||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -562.407 | 0 | -100,00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -347.173 | 0 | -100,00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -1.331.816 | 0 | -100,00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 281.203 | 947.111 | 42,23 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 173.586 | 216.451 | 404,96 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 665.908 | 665.908 | |||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1.778.594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3.385.728 | ||||||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series D Preferred Stock |
C - Conversion | -21.496 | 0 | -100,00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series D Preferred Stock |
C - Conversion | -85.989 | 0 | -100,00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series C Preferred Stock |
C - Conversion | -1.428.432 | 0 | -100,00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series C Preferred Stock |
C - Conversion | -5.713.739 | 0 | -100,00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series B Preferred Stock |
C - Conversion | -6.195.632 | 0 | -100,00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series B Preferred Stock |
C - Conversion | -24.782.551 | 0 | -100,00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series A Preferred Stock |
C - Conversion | -1.823.036 | 0 | -100,00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series A Preferred Stock |
C - Conversion | -7.292.145 | 0 | -100,00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 21.496 | 9.468.596 | 0,23 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 85.989 | 37.874.424 | 0,23 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 1.428.432 | 9.447.100 | 17,81 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 5.713.739 | 37.788.435 | 17,81 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 6.195.632 | 8.018.668 | 339,85 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 24.782.551 | 32.074.696 | 339,85 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 1.823.036 | 1.823.036 | |||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 7.292.145 | 7.292.145 | |||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22.924.794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11.468.283 | ||||||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -781.860 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -195.466 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -195.466 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1.781.843 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -593.948 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -593.948 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -5.000.000 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -5.000.000 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3.830.402 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -15.323.593 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 781.860 | 2.563.703 | 43,88 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 195.466 | 5.789.414 | 3,49 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 195.466 | 5.789.414 | 3,49 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 1.781.843 | 1.781.843 | |||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 593.948 | 5.593.948 | 11,88 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 593.948 | 5.593.948 | 11,88 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 5.000.000 | 5.000.000 | |||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 5.000.000 | 5.000.000 | |||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 3.830.402 | 3.830.402 | |||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 15.323.593 | 15.323.593 | |||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -4.643.963 | 0 | -100,00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -18.611.110 | 0 | -100,00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-3 Preferred Stock |
C - Conversion | -8.333.000 | 0 | -100,00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-2 Preferred Stock |
C - Conversion | -5.416.667 | 0 | -100,00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -10.102.055 | 0 | -100,00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -12.536.945 | 0 | -100,00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 281.250 | 18.233.403 | 1,57 | 16,00 | 4.500.000 | 291.734.448 | |
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
C - Conversion | 14.622.143 | 17.952.153 | 439,10 | ||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6.660.018 | ||||||||
2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -54.293 | 0 | -100,00 | ||||
2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -306.222 | 612.442 | -33,33 | ||||
2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -1.295.997 | 2.378.663 | -35,27 | ||||
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -10.293 | 106.787 | -8,79 | 3,10 | -31.908 | 331.040 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -41.178 | 426.885 | -8,80 | 3,10 | -127.652 | 1.323.344 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -3.118 | 117.080 | -2,59 | 3,16 | -9.853 | 369.973 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -12.482 | 468.063 | -2,60 | 3,16 | -39.443 | 1.479.079 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -47.090 | 120.198 | -28,15 | 3,17 | -149.275 | 381.028 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -188.367 | 480.545 | -28,16 | 3,17 | -597.123 | 1.523.328 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -28.163 | 167.288 | -14,41 | 3,18 | -89.558 | 531.976 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -112.731 | 668.912 | -14,42 | 3,18 | -358.485 | 2.127.140 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -64.509 | 195.451 | -24,81 | 3,75 | -241.909 | 732.941 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -258.214 | 781.643 | -24,83 | 3,75 | -968.302 | 2.931.161 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -10.778 | 259.960 | -3,98 | 3,39 | -36.537 | 881.264 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -43.139 | 1.039.857 | -3,98 | 3,39 | -146.241 | 3.525.115 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -1.939 | 270.738 | -0,71 | 3,31 | -6.418 | 896.143 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -7.761 | 1.082.996 | -0,71 | 3,31 | -25.689 | 3.584.717 | |
2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -536 | 272.677 | -0,20 | 4,16 | -2.230 | 1.134.336 | |
2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -2.145 | 1.090.757 | -0,20 | 4,16 | -8.923 | 4.537.549 | |
2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -8.802 | 273.213 | -3,12 | 4,18 | -36.792 | 1.142.030 | |
2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -35.209 | 1.092.902 | -3,12 | 4,18 | -147.174 | 4.568.330 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -8.145 | 282.015 | -2,81 | 4,51 | -36.734 | 1.271.888 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -32.597 | 1.128.111 | -2,81 | 4,51 | -147.012 | 5.087.781 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -52.985 | 1.833.802 | -2,81 | 4,51 | -238.962 | 8.270.447 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -3.108 | 290.160 | -1,06 | 4,63 | -14.390 | 1.343.441 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -12.441 | 1.160.708 | -1,06 | 4,63 | -57.602 | 5.374.078 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -20.221 | 1.886.787 | -1,06 | 4,63 | -93.623 | 8.735.824 | |
2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -50.271 | 0 | -100,00 | ||||
2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -300.000 | 691.060 | -30,27 | ||||
2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -1.200.000 | 2.764.256 | -30,27 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -444.995 | 0 | -100,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1.779.981 | 0 | -100,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-3 Preferred Stock |
C - Conversion | -1.500.000 | 0 | -100,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-3 Preferred Stock |
C - Conversion | -6.000.000 | 0 | -100,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1.000.000 | 0 | -100,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock |
C - Conversion | -4.000.000 | 0 | -100,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-1 Preferred Stock |
C - Conversion | -200.000 | 0 | -100,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-1 Preferred Stock |
C - Conversion | -800.000 | 0 | -100,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 80.000 | 918.664 | 9,54 | 12,50 | 1.000.000 | 11.483.300 | |
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 320.000 | 3.674.660 | 9,54 | 12,50 | 4.000.000 | 45.933.250 | |
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 118.665 | 838.664 | 16,48 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 474.661 | 3.354.660 | 16,48 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 400.000 | 719.999 | 125,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.600.000 | 2.879.999 | 125,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 266.666 | 319.999 | 500,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.066.666 | 1.279.999 | 500,00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 53.333 | 53.333 | |||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 213.333 | 213.333 | |||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426.664 | ||||||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -33.514 | 0 | -100,00 | ||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | 7 | 33.514 | 0,02 | ||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | 33.507 | 33.514 | 478.671,43 | ||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -200.000 | 1.925.462 | -9,41 | ||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -800.000 | 8.022.420 | -9,07 | ||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -599.297 | 0 | -100,00 | 27,60 | -16.540.597 | ||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -80.141 | 1.925.462 | -4,00 | 27,60 | -2.211.892 | 53.142.751 | |
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -320.562 | 2.734.994 | -10,49 | 27,60 | -8.847.511 | 75.485.834 | |
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -199.999 | 0 | -100,00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1.051.060 | 0 | -100,00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-1 Preferred Stock |
C - Conversion | -1.325.708 | 0 | -100,00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -800.001 | 0 | -100,00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-2 Preferred Stock |
C - Conversion | -4.204.240 | 0 | -100,00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-1 Preferred Stock |
C - Conversion | -5.302.834 | 0 | -100,00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 76.922 | 991.060 | 8,41 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 404.253 | 914.138 | 79,28 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 509.885 | 509.885 | |||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 307.692 | 3.964.256 | 8,41 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 1.617.015 | 3.656.564 | 79,28 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 2.039.549 | 2.039.549 | |||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -454.546 | 0 | -100,00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.818.181 | 0 | -100,00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -224.719 | 0 | -100,00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -898.877 | 0 | -100,00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -599.297 | 0 | -100,00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1.526.338 | 0 | -100,00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -6.105.362 | 0 | -100,00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 599.297 | 599.297 | |||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 2.205.603 | 2.205.603 | |||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 8.822.420 | 8.822.420 | |||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6.111.112 | ||||||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -631.133 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -629.851 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -819.493 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.053.201 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -774.527 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -128.567 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 741.755 | 2.374.571 | 45,43 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 1.632.816 | 1.632.816 | |||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -420.053 | 0 | -100,00 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.680.213 | 0 | -100,00 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1.050.000 | 0 | -100,00 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -4.200.000 | 0 | -100,00 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -9.000.000 | 0 | -100,00 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 32.912 | 293.268 | 12,64 | 10,00 | 329.120 | 2.932.680 | |
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 131.722 | 1.173.149 | 12,65 | 10,00 | 1.317.220 | 11.731.490 | |
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 214.095 | 1.907.008 | 12,65 | 10,00 | 2.140.950 | 19.070.080 | |
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 231.504 | 260.356 | 802,38 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 926.017 | 1.041.427 | 802,37 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 1.417.323 | 1.692.913 | 514,29 | ||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695.442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535.262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448.704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
275.590 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
115.410 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
28.852 |